In this episode, Dennis Walker talks with Acacea Lewis, where she shares insights accrued from her extensive experience supporting people doing high dose journey work and integration, and shares her thoughts about the emergent ‘psychedelics industry’ as well as the importance of learning how to cultivate presence.
In this episode, David Flores speaks with Matt Zemon, the co-founder of Happy and author of Psychedelic for Everyone. They open up about deeply personal stories about their childhood, with Matt sharing a beautiful story about connecting with his son Cole.
Pop star says in new interview that tripping on psilocybin enabled him, for the first time, to “write actual stories about my life and put it into my music.”
In this Psychedelic Spotlight exclusive, we speak with California Senator,…
Today, we have a different episode for you..Usually we talk about all the things I am excited for when it comes to MindMed and MindMed stock, but today, we will visit the darker side by discussing how risky is the MindMed stock.
It is important for all psychedelic investors to grasp that MindMed is not a sure deal. Yes, I believe that long term it will succeed, but there are certain things that could go wrong.
We will cover the very real risks involved in investing in MindMed such as:
1. The possibility of MindMed’s medicines being inefficacious
– Whether of not MMED’s clinical trials succeed
2.MindMed’s incertain long term profitability
– Can the company scale production and training protocols?
3.MindMed Stock volatility
– MindMed’s market cap
– Future short interests
MindMed trades on the Canadian NEO Market as (MMED) and American OTC market as (MMEDF)
MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/wp-content/uploads/2020/11/end-of-year-2019-discussion.pdf
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own
A year after a Johns Hopkins psilocybin-assisted therapy study, researchers find the number of people who benefited from receiving two doses actually increased.
“After adjusting for a range of potential confounders, psychedelic use remained independently associated with a significantly reduced odds of subsequent daily opioid use,” researchers say.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
